Multiple Endocrine Neoplasia Type 2b

This is also an inherited genetic condition causing tumors in specific glands. It mainly affects the thyroid gland (causing a specific type of thyroid cancer) and the adrenal glands (causing tumors that produce hormones). Unlike the other type, it doesn't usually affect the parathyroid glands. It can also cause other symptoms like skin growths and digestive problems.

Condition

What people with Multiple Endocrine Neoplasia Type 2b report

Every report comes from a Lived member, sent anonymously.

Have you had Thyroid Surgery for Multiple Endocrine Neoplasia Type 2b?

NameHow it went

About Multiple Endocrine Neoplasia Type 2b

What It Is

Multiple endocrine neoplasia type 2B (MEN2B) is a rare inherited condition that causes tumors in hormone-producing glands. Its most important feature is a very high risk of medullary thyroid cancer, a cancer that starts in the C cells of the thyroid (cells that make a hormone called calcitonin). In MEN2B this cancer tends to begin in early childhood and behaves more aggressively than in related conditions, which is why early recognition matters so much. About half of people with MEN2B also develop a pheochromocytoma, an adrenal gland tumor that releases adrenaline-like hormones and can drive blood pressure dangerously high. MEN2B also has features outside the hormone glands. Many people have small, soft bumps (mucosal neuromas) on the lips, tongue and inner eyelids, fuller lips, and a tall, slender build with long limbs. Overgrowth of nerve tissue in the bowel can cause long-standing constipation, diarrhea or a swollen belly. Some babies cannot make tears when they cry. Nearly all affected children show at least one of these features, and they are often the first clue. MEN2B is one of three forms of MEN type 2 and accounts for about 5 percent of cases. Unlike the more common type 2A (MEN2A), it does not cause overactive parathyroid glands.

Causes & Risk Factors

MEN2B is caused by a change (variant) in the RET gene. RET makes a protein that tells cells when to grow and divide. The MEN2B variant switches that signal on permanently, so certain cells keep growing without the usual controls. In almost all people with MEN2B the change is the same one, identified by the code M918T, which carries the highest cancer risk of any RET variant. The condition is passed on in an autosomal dominant way: one altered copy of the gene is enough, and each child of an affected parent has a 50 percent chance of inheriting it. However, many people with MEN2B, by some estimates most, are the first in their family to have it because the variant arose new in them. Because there is no family history to prompt testing, these children are often diagnosed later, after the thyroid cancer has already started.

How It's Diagnosed

Diagnosis is confirmed with a genetic test for the RET variant, usually a blood or saliva sample. Testing is recommended for anyone with features of MEN2B, for anyone diagnosed with medullary thyroid cancer, and for the parents, siblings and children of a person known to carry a RET variant. Once a family's variant is known, testing can also be done before birth or on embryos during in vitro fertilization if parents want that option. After the genetic diagnosis, doctors look for the tumors themselves. Calcitonin, the hormone made by thyroid C cells, is measured in the blood: a rising level signals medullary thyroid cancer, and a high level suggests the cancer may have spread. In infants and young children, whose calcitonin is naturally higher, results are read against age-appropriate ranges. A related blood marker, CEA (carcinoembryonic antigen), is often checked as well. A neck ultrasound shows the thyroid and nearby lymph nodes. To look for pheochromocytoma, doctors measure metanephrines (breakdown products of adrenaline and noradrenaline) in the blood or in urine collected over 24 hours, followed by adrenal imaging if the results are high. In children who were not tested early, the visible features (bumps on the lips and tongue, constipation from infancy, absent tears) are often what lead a clinician to suspect MEN2B.

Treatment Options

The main treatment is removing the whole thyroid gland (total thyroidectomy) before the cancer can spread. For children known to carry the MEN2B variant, guidelines recommend this surgery within the first year of life. When the operation is done this early, it can prevent the cancer or remove it while it is still confined to the thyroid. When MEN2B is diagnosed later, surgery also removes nearby lymph nodes in the neck, and the chance of a cure is lower. Before any thyroid surgery, and before other operations, pheochromocytoma has to be ruled out with blood or urine tests. If one is found, it is removed first, after medicine to bring blood pressure and pulse under control, because an undetected tumor can cause dangerous blood pressure surges during anesthesia. Pheochromocytomas often occur in both adrenal glands over time, so some surgeons leave part of the gland behind to preserve its normal hormone production and avoid lifelong steroid hormone replacement. After the thyroid is removed, a daily thyroid hormone pill (levothyroxine) replaces what the gland made. When medullary thyroid cancer has spread and is growing or causing symptoms, targeted pills can slow it. Selpercatinib (Retevmo) directly blocks the overactive RET protein, is approved for people 2 years and older with RET-mutated medullary thyroid cancer that needs drug treatment, and is now commonly the first choice. Older kinase inhibitors, vandetanib (Caprelsa) and cabozantinib (Cometriq), are alternatives. These medicines control disease rather than cure it and have significant side effects that need regular monitoring. Radiation may be used for cancer that could not be fully removed.

What to Expect

MEN2B is lifelong, and the outlook depends heavily on when it is found. A child who has the thyroid removed in infancy has the best chance of never developing spreading cancer. People diagnosed in later childhood or adulthood often already have cancer in the neck lymph nodes, and some live with cancer that persists or returns. Medullary thyroid cancer can still grow slowly for years, and newer targeted medicines have widened the options for people whose disease progresses. Follow-up continues for life. Blood calcitonin (and often CEA) is checked regularly after surgery, typically once a year when results are stable: an undetectable level is reassuring, while a rising level prompts imaging. Yearly blood or urine metanephrine tests screen for pheochromocytoma, starting at an age the care team sets based on the specific gene change. Daily thyroid hormone is checked with routine blood tests. Many people also live with ongoing bowel problems, and some have bone or joint differences that need orthopedic care. Pregnancy needs planning. Anyone with MEN2B who could become pregnant should be screened for pheochromocytoma before trying to conceive, or as early as possible in an unplanned pregnancy, because an undetected tumor is dangerous during pregnancy and delivery. Genetic counseling helps with family planning and with testing relatives. Because MEN2B is rare, care is best coordinated by an endocrinologist and surgeons with experience in hereditary thyroid cancer.

When to Seek Help

Ask about genetic testing for a child who has bumps on the lips or tongue together with persistent constipation, absent tears or a very slender build, and for anyone with medullary thyroid cancer or a relative with a RET variant. A new lump in the neck should be checked soon. Contact the care team promptly about episodes of pounding headache, heavy sweating, a racing or pounding heart, or high blood pressure readings, which can signal a pheochromocytoma, and about ongoing diarrhea that is new or worsening. An episode that comes with chest pain, shortness of breath, a severe headache with confusion, vision changes, weakness or numbness, or trouble speaking needs emergency care: call 911. Before any surgery, procedure, new medicine or pregnancy, make sure the clinicians involved know about MEN2B and that pheochromocytoma screening is up to date.

Questions to Ask Your Doctor

  1. 1.Has my child been tested for the RET variant, and when should the thyroid be removed?
  2. 2.What do my current calcitonin and CEA levels mean, and how often should they be checked?
  3. 3.When should screening for pheochromocytoma start, and which test will we use?
  4. 4.Should my parents, siblings or children have genetic testing, and how do we arrange genetic counseling?
  5. 5.If the cancer has spread, would a RET-targeted medicine such as selpercatinib help, and what side effects should I watch for?

Last reviewed • Oct 2026

Educational content, not medical advice.